gerg
makara
john
athanasopoulo
affin
technolog
appli
sever
stage
drug
discoveri
process
rang
target
identif
purif
identif
preclin
candid
detect
ligandmacromolecul
interact
lead
discoveri
best
studi
power
techniqu
although
affin
method
widespread
use
decad
recent
mani
report
emerg
util
primari
affin
screen
larg
librari
small
molecul
fragment
begun
produc
result
challeng
target
furthermor
secondari
assay
affin
method
open
new
avenu
tackl
import
medicin
chemistri
task
lead
gener
critic
first
step
drug
discoveri
process
past
decad
highthroughput
screen
ht
corpor
compound
deck
emerg
primari
paradigm
hit
lead
discoveri
typic
target
interrog
million
discret
compound
parallel
ht
era
thu
far
deliv
mix
result
hit
rate
target
tend
extrem
low
high
two
key
factor
like
respons
first
compound
deck
industri
skew
compound
distribut
favor
specif
wellstudi
protein
subfamili
second
importantli
novel
target
sampl
druglik
chemistri
space
million
compound
inadequ
consist
deliv
sever
divers
lead
class
challeng
face
ht
technolog
includ
high
falseposit
falseneg
rate
need
report
assay
limit
throughput
impos
test
compound
individu
address
issu
affin
bioaffin
screen
approach
emerg
orthogon
method
earli
lead
discoveri
affinitybas
techniqu
readout
typic
qualit
quantit
signal
base
physic
interact
macromolecul
rna
dna
protein
smallmolecul
partner
approach
sever
advantag
biochem
assay
druglik
fragmentlik
method
see
glossari
first
capabl
sampl
mixtur
includ
natur
product
rather
discret
entiti
thu
enabl
explor
larger
chemic
space
without
concomit
increas
number
sampl
second
abil
investig
multipl
form
macromolecul
variou
ternari
complex
activ
inactiv
form
form
without
cofactor
third
possibl
carri
assay
smallmolecul
concentr
much
higher
lower
correspond
biochem
assay
last
approach
elimin
mani
assay
artifact
aris
nonspecif
aggreg
fluoresc
absorpt
quench
downsid
affinitybas
technolog
deliv
function
readout
thu
affin
hit
requir
biochem
cellular
vivo
valid
nevertheless
advantag
affin
techniqu
extend
use
followup
secondari
screen
especi
field
atpdepend
enzym
articl
review
subset
affin
techniqu
shown
valuabl
lead
discoveri
tabl
provid
sever
exampl
demonstr
success
consid
achiev
perspect
technolog
drug
discoveri
affin
select
techniqu
classifi
homogen
heterogen
heterogen
screen
environ
creat
immobil
either
macromolecul
interest
small
molecul
reactiv
surfac
follow
static
flowbas
analysi
bind
contrast
homogen
environ
leav
macromolecular
smallmolecul
speci
interact
nativ
state
follow
bind
event
qualit
quantit
assess
interact
made
use
one
mani
avail
detector
use
affin
screen
nuclear
magnet
reson
nmr
mass
spectroscopi
ms
xray
crystallographi
surfac
plasmon
reson
spr
subset
techniqu
employ
filtrat
step
detect
specif
detail
affin
screen
techniqu
review
consid
recent
develop
platform
affin
select
druglik
compound
autom
ligand
identif
system
ali
screen
platform
neogenesi
http
wwwneogenesiscom
one
earliest
affin
select
technolog
capabl
screen
larg
number
compound
key
step
ali
separ
desir
proteinligand
complex
nonbind
compon
dissoci
complex
revers
phase
chromatographi
mass
detect
part
lead
discoveri
effort
antiinfect
target
escherichia
coli
dihydrofol
reductas
total
compound
mixtur
screen
identifi
compound
figur
advantag
improv
sampl
chemistri
space
demonstr
discoveri
singl
compound
multimillion
member
librari
bsecretas
enzym
crucial
alzheim
diseas
compound
select
possess
uniqu
bind
mode
could
optim
form
potent
inhibitor
enzym
gener
ali
platform
demonstr
divers
set
target
glossari
druglik
molecul
typic
molecul
molecular
weight
rang
da
either
pass
violat
one
compon
ruleoff
lipinski
rule
oral
bioavail
leadlik
molecul
typic
molecul
molecular
weight
rang
da
enabl
lead
growth
medicin
chemistri
optim
toward
clinic
candid
still
pass
ruleoff
fragmentlik
molecul
typic
molecul
molecular
weight
rang
da
higher
solubl
druglik
molecul
enabl
screen
high
micromolar
millimolar
smallmolecul
concentr
fragmentbas
drug
lead
discoveri
lead
gener
techniqu
call
primari
screen
weakbind
ic
mm
fragmentlik
molecul
follow
optim
toward
lead
rather
primari
screen
potent
ic
nm
druglik
molecul
via
ht
advantag
former
better
sampl
chemistri
space
number
compound
relev
drug
discoveri
grow
exponenti
molecular
weight
fragment
evolut
fragment
optim
techniqu
typic
involv
systemat
explor
structureact
relationship
along
variou
substitut
vector
fragment
hit
sitedirect
fragment
screen
fragment
optim
techniqu
typic
involv
screen
fragment
librari
presenc
anoth
fragment
ad
satur
concentr
bind
mode
latter
fragment
typic
known
previou
studi
new
hit
second
screen
would
target
new
bind
site
hit
could
later
subject
fragment
link
previous
identifi
fragment
also
disclos
practic
approach
includ
sequenc
event
ali
step
carri
complet
decoupl
last
unlik
ali
speedscreen
take
advantag
parallel
capabl
use
format
typic
screen
campaign
compris
approxim
compound
mixtur
test
solubl
globular
protein
research
abbott
http
wwwabbottcom
use
ultrafiltr
separ
binder
oncolog
target
bclx
l
nonbind
mixtur
compound
part
studi
compar
result
fluoresc
polar
assay
affin
select
mass
spectrometri
asm
platform
compound
screen
duplic
binder
affin
mm
identifi
asm
author
suggest
valuabl
appli
differ
screen
method
lower
falseneg
rate
similar
conclus
made
screen
statist
far
upstream
element
bind
protein
fbp
capillari
electrophoresi
ce
also
shown
reliabl
tool
studi
molecular
interact
ce
use
interrog
crude
natur
product
broth
potenti
lead
bind
event
discern
monitor
migrat
time
proteinligand
complex
versu
protein
alon
refer
point
upon
complex
format
conform
chang
protein
expos
differ
residu
surfac
event
chang
mobil
complex
relat
charg
environ
frontal
affin
chromatographi
coupl
mass
spectromet
facm
base
immobil
target
onto
solid
support
small
molecul
infus
continu
immobil
target
monitor
mass
spectromet
depend
affin
strength
extract
ion
current
binder
observ
later
elut
time
compar
noninteract
control
compound
furthermor
shape
individu
extract
ion
current
provid
crude
approxim
rel
affin
competit
condit
studi
discov
molecul
bind
surfac
spike
protein
sever
acut
respiratori
syndrom
coronaviru
sarscov
two
small
molecul
report
compound
identifi
extract
chines
herb
use
facm
approach
use
resolv
power
fourier
transform
ion
cyclotron
reson
mass
spectrometri
research
compound
deriv
affin
screen
druglik
molecul
see
text
detail
abl
studi
noncoval
interact
rnaligand
complex
without
need
separ
step
detect
platform
term
multitarget
affinityspecif
screen
allow
multiplex
rna
construct
small
molecul
howev
gener
techniqu
target
remain
demonstr
part
quest
screen
increas
number
small
molecul
dnatag
librari
devis
affin
screen
immobil
target
binder
amplifi
pcr
reveal
chemic
ident
technolog
rather
new
limit
synthet
falseposit
falseneg
rate
yet
clear
detail
found
http
wwwnuevolutioncom
http
wwwpraeciscom
cost
effici
scalabl
lead
deliveryr
issu
ht
becam
appar
past
decad
new
term
leadlik
fragmentlik
fragmentbas
drug
discoveri
surfac
see
glossari
signific
resourc
research
dedic
identifi
techniqu
measur
bind
small
molecular
weight
da
molecul
fragment
macromolecul
inher
difficulti
use
biochem
tool
detect
weak
ligand
often
millimolar
concentr
necessit
search
affinitytyp
readout
year
nmr
abbott
vertex
http
wwwvpharmcom
xray
crystallographi
abbott
astex
http
wwwastextherapeuticscom
plexxikon
http
wwwplexxikoncom
emerg
method
choic
conduct
fragmentbas
lead
discoveri
intrigu
altern
coval
trap
fragment
k
depend
manner
also
develop
sunesi
thiolreact
probe
http
wwwsunesiscom
fragmentbas
approach
ideal
find
new
warhead
small
function
group
ensembl
function
group
bind
crucial
residu
conserv
within
protein
famili
advantag
demonstr
protein
tyrosin
phosphatas
valid
histor
challeng
target
implic
type
ii
diabet
proteinbas
nmr
fragment
screen
detect
chang
nmr
spectra
protein
ligand
bind
use
identifi
sever
phosphat
mimic
oxalylarylaminobenzo
acid
figur
prove
cell
permeabl
isoxazolecarboxyl
acid
latter
link
noncompetit
fragment
identifi
anoth
nmr
screen
result
develop
monocharg
inhibitor
cellular
activ
search
aminoglycosid
mimet
e
coli
asit
rna
nmrbase
screen
member
librari
use
identifi
sever
differ
chemic
seri
two
aminopyridin
could
rapidli
advanc
potent
deriv
low
micromolar
rang
structur
activ
relationship
determin
nmr
sar
nmr
instrument
develop
abbott
matrix
metalloproteinas
program
identifi
key
biphenyl
group
fragment
link
hydroxam
acid
follow
medicin
chemistri
optim
ultim
result
develop
candid
treat
cancer
sitedirect
fragment
screen
fragment
evolut
see
glossari
also
use
discov
optim
lead
antiapoptot
famili
ultim
lead
compound
well
toler
shown
caus
tumor
regress
multipl
cancer
cell
line
either
singl
agent
combin
chemotherapeut
proteinbas
nmr
fragment
screen
also
recent
extend
insolubl
protein
unlik
proteinbas
nmr
shape
techniqu
reli
detect
chang
nmr
spectra
small
molecul
advantag
proteinbas
method
limit
impos
size
protein
requir
label
protein
lower
reagent
consumpt
downsid
structur
inform
protein
bind
site
rel
bind
mode
differ
fragment
discern
shape
method
appli
preht
owe
minim
develop
time
postht
fail
target
exemplifi
map
kinas
adipocyt
lipidbind
protein
close
integr
xray
crystallographi
molecular
model
report
essenti
optim
initi
fragment
hit
past
decad
data
analysi
crystal
soak
technolog
throughput
matur
level
xray
crystallographi
appli
parallel
detect
weakli
bind
fragment
although
drawback
falseneg
long
develop
time
novel
unknown
protein
protein
consumpt
still
remain
structureguid
fragment
evolut
make
technolog
attract
option
fragment
simpli
screen
small
mixtur
member
prefilt
biochem
assay
limit
set
scaffold
crystal
proofofprincipl
latter
approach
recent
disclos
phosphodiesteras
studi
ester
develop
use
member
scaffold
librari
structurebas
optim
comprehens
studi
five
target
thrombin
rnase
demonstr
weak
fragment
inde
identifi
use
highthroughput
crystallographi
chemic
seri
evolut
fragment
lead
illustr
program
although
studi
clearli
show
potenti
underli
technolog
lead
gener
strong
relianc
structurebas
design
optim
make
discoveri
truli
novel
molecular
framework
unlik
use
thiolreact
probe
research
sunesi
abl
screen
new
chemic
motif
activ
aid
breakaway
tether
cystein
residu
introduc
outsid
enzym
activ
site
coval
modifi
flexibl
linker
hold
thiol
end
group
protein
interrog
fragment
screen
unveil
acid
monoamid
moieti
equipot
competit
inhibitor
phosphotyrosin
biochem
assay
differ
studi
electrophil
screen
found
select
react
cystein
away
catalyt
site
coval
modif
reduc
enzymat
activ
compound
deriv
fragmentbas
techniqu
see
text
detail
via
alloster
perturb
neighbor
phosphotyrosinebind
site
competit
affin
screen
cytokin
hormon
use
fragment
presenc
previous
known
inhibitor
reveal
seri
compound
show
cooper
bind
previous
known
molecul
fragment
decomposit
known
inhibitor
addit
competit
fragment
screen
invalu
develop
nanomolar
inhibitor
cellular
activ
fragment
librari
exchang
thiol
unveil
alloster
bind
site
caspas
well
agonist
antagonist
fragment
gproteincoupl
receptor
result
elegantli
demonstr
one
key
advantag
affinityrel
techniqu
abil
studi
screen
differ
enzym
form
find
compound
affin
alloster
adjac
bind
site
fragmentbas
lead
discoveri
shown
success
year
deliv
effici
lead
rel
high
freeenergi
bind
per
heavi
atom
approach
rel
new
remain
seen
whether
smaller
hydrophil
lead
entri
point
medicin
chemistri
actual
yield
smaller
drug
candid
fail
less
often
clinic
focu
affin
techniqu
discuss
far
either
increas
throughput
tradit
librari
enabl
detect
weakli
bind
fragment
low
throughput
help
sampl
discoveri
space
repres
opposit
extrem
immobil
small
organ
molecul
microarray
enabl
use
spr
detect
weak
interact
method
practic
extens
establish
biacor
tm
technolog
fragment
may
hold
promis
ht
leadlik
small
molecul
model
studi
use
factor
viia
focus
set
immobil
compound
confirm
bind
posit
control
paminobenzamidin
mm
identifi
sever
new
fragment
ligand
followup
biochem
activ
tendenc
form
crystal
howev
correl
observ
spr
signal
develop
approach
may
matur
semiquantit
screen
techniqu
qualit
filter
highthroughput
affin
method
nmr
xray
crystallographi
found
way
mani
applic
includ
mechanist
competit
studi
determin
bind
kinet
compound
profil
select
screen
use
homogen
affin
select
recent
shown
distinguish
direct
alloster
competit
behavior
could
also
establish
compound
rank
mixtur
format
titrat
experi
unknown
compound
ligand
method
also
use
rank
new
deriv
optim
studi
spr
analysi
bind
kinet
biacor
tm
standard
determin
associ
dissoci
rate
constant
k
major
drawback
requir
immobil
one
bind
partner
typic
protein
compens
lack
need
radiolabel
materi
select
particularli
crucial
factor
develop
drug
candid
atpdepend
enzym
signific
effort
express
develop
assay
grow
number
kinas
mutant
counterscreen
studi
owe
earli
report
find
offtarget
liabil
potenti
advers
effect
distant
section
kinas
dendogram
immobil
inhibitor
use
map
atpbind
site
interact
mani
target
conceiv
inhibitor
might
link
via
multipl
orient
avoid
falseneg
aris
linker
interfer
nevertheless
sever
surprisingli
tight
offtarget
interact
identifi
arylimidazol
pyrido
pyrimidin
kinas
inhibitor
class
semihomogen
variat
techniqu
also
develop
requir
immobil
small
number
compound
studi
atpcompetit
small
molecul
enzym
approach
highli
promiscu
inhibitori
constant
ic
mm
bait
molecul
immobil
solid
support
via
biotinyl
linker
phage
tag
protein
introduc
along
studi
compound
free
solut
free
compound
bind
protein
elut
macromolecul
slower
extens
interact
bait
compound
solid
support
amount
protein
bound
support
quantifi
either
phage
plaqu
assay
quantit
pcr
high
sensit
plot
function
test
compound
concentr
entir
enzym
panel
run
singl
experi
unlik
biochem
assay
result
depend
atp
concentr
cours
interest
novel
interact
known
compound
new
target
found
profil
techniqu
also
serv
lead
discoveri
tool
initi
chemistri
effort
deriv
new
therapeut
today
highthroughput
screen
although
frequent
effect
might
suffici
pharmaceut
industri
futur
lead
discoveri
need
affin
method
aim
eas
problem
variou
way
new
advanc
technolog
sure
follow
better
success
rate
improv
lead
discoveri
process
also
enhanc
understand
smallmolecul
bind
protein
end
protein
druggabl
index
propos
base
nmr
fragment
screen
data
predict
classif
protein
via
smallmolecul
interact
highli
intrigu
concept
theoret
experiment
studi
requir
sampl
rate
differ
discoveri
librari
druglik
fragment
might
necessari
major
mileston
reach
